Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 49 citas
Etiquetas de revisión
Cuestionario de frecuencia de consumoSin ajuste declarado por estilo de vidaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
- Consumo medido con
- Cuestionario de frecuencia de consumo
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Cancer Institute
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- NCI NIH HHS
- Gobierno
- NIDDK NIH HHS
- Subvenciones
- National Cancer Institute (R01CA149222); National Cancer Institute (K07CA148894); National Cancer Institute (R01CA118553); National Institute of Diabetes and Digestive and Kidney Diseases (P30DK046200); National Cancer Institute (U10 CA180821); National Cancer Institute (U10-CA180888); National Cancer Institute (U10CA180836); National Cancer Institute (U10 CA180867); National Cancer Institute (U10 CA180791); National Cancer Institute (R01CA169141); National Cancer Institute (R35CA197735); National Cancer Institute (R01 CA205406); National Cancer Institute (U10CA180820); National Cancer Institute (U10-CA180882); National Cancer Institute (U10 CA138561); National Cancer Institute (P50-CA127003); National Cancer Institute (UG1 CA189974); National Cancer Institute (UG1CA189858); National Cancer Institute (#P30-CA008748)
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-02-28 · J Clin Oncol · vol. 36 · número 11 · págs. 1112–1120
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 66 citas · más que el 97% de estudios similares · 5.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 87 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Nuts composition and effects · Tea Polyphenols and Effects · Nutritional Studies and Diet
- Palabras clave
- Medicine, Hazard ratio, Internal medicine, Colorectal cancer, Glycemic load, Proportional hazards model, Cancer, Type 2 diabetes, Observational study, Prospective cohort study, Diabetes mellitus, Surgery, Glycemic index, Gastroenterology, Glycemic, Confidence interval, Insulin, Endocrinology
- MeSH
- humans, nuts, colonic neoplasms, neoplasm recurrence, local, antineoplastic combined chemotherapy protocols, neoplasm staging, treatment outcome, chemotherapy, adjuvant, diet, incidence, risk factors, prospective studies, nutritive value, time factors, aged, middle aged, diet records, female, male, randomized controlled trials as topic, protective factors
22 autores
- Temidayo A. Fadelu
- Sui Zhang
- Donna Niedzwiecki
- Xing Ye
- Leonard B. Saltz
- Robert J. Mayer
- Rex Bradford Mowat
- Renaud Whittom
- Alexander Hantel
- Al B. Benson
- Daniel M. Atienza
- Michael J. Messino
- Hedy Lee Kindler
- Alan Paul Venook
- Shuji Ogino
- Kimmie Ng
- Kana Wu
- Walter Churchill Willett
- Edward L. Giovannucci
- Jeffrey A. Meyerhardt
- Ying Bao
- Charles S. Fuchs
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose Observational studies have reported increased colon cancer recurrence and mortality in patients with states of hyperinsulinemia, including type 2 diabetes, obesity, sedentary lifestyle, and high glycemic load diet. Nut intake has been associated with a lower risk of type 2 diabetes, metabolic syndrome, and insulin resistance. However, the effect of nut intake on colon cancer recurrence and survival is not known. Patients and Methods We conducted a prospective, observational study of 826 eligible patients with stage III colon cancer who reported dietary intake on food frequency questionnaires while enrolled onto a randomized adjuvant chemotherapy trial. Using Cox proportional hazards regression, we assessed associations of nut intake with cancer recurrence and mortality. Results After a median follow-up of 6.5 years, compared with patients who abstained from nuts, individuals who consumed two or more servings of nuts per week experienced an adjusted hazard ratio (HR) for disease-free survival of 0.58 (95% CI, 0.37 to 0.92; Ptrend = .03) and an HR for overall survival of 0.43 (95% CI, 0.25 to 0.74; Ptrend = .01). In subgroup analysis, the apparent benefit was confined to tree nut intake (HR for disease-free survival, 0.54; 95% CI, 0.34 to 0.85; Ptrend = .04; and HR for overall survival, 0.47; 95% CI, 0.27 to 0.82; Ptrend = .04). The association of total nut intake with improved outcomes was maintained across other known or suspected risk factors for cancer recurrence and mortality. Conclusion Diets with a higher consumption of nuts may be associated with a significantly reduced incidence of cancer recurrence and death in patients with stage III colon cancer.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.